On 12 November 2026, Celltrion announced that it has filed an application with Australia’s Therapeutic Goods Administration for approval of Besequma® (CT-P55), biosimilar to Novartis’ Cosentyx® (secukinumab). The application is for all approved indications of Cosentyx®.
Celltrion’s Australian application follows its submission of marketing approval applications for CT-P55 in Europe and the US (July 2026), Korea (June 2026) and Canada (May 2026).
Celltrion presented results from its Phase 1 trial for CT-P55 in September 2025. In February 2026, Celltrion received approval from the EMA to reduce patient numbers enrolled in its global Phase 3 clinical trial for CT-P55.
On 26 October 2026, Bio-Thera announced that it received the first approval for a secukinumab biosimilar by any major regulatory agency in the world when it obtained marketing authorisation in China for BAT2306, marketed as Youzhuomei™. BAT2306/Youzhuomei™ is approved in China for psoriasis, ankylosing spondylitis and psoriatic arthritis.
Secukinumab biosimilars are under development by at least Taizhou Mabtech Pharmaceutical (phase 1 trial of CMAB015 completed in 2023) and Livzon Pharmaceutical Group (phase 3 clinical trial of LZM012 in plaque psoriasis). In June 2026, CSPC Pharmaceutical announced that China’s National Medical Products Administration (NMPA) had accepted a marketing authorisation application for its Secukinumab Injection.
